Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Dabrafenib/trametinib

Dabrafenib/trametinib Reactions 1704, p130 - 2 Jun 2018 Blurred vision, nausea and peripheral oedema: case report A 51-year-old woman developed occasional nausea, peripheral oedema and blurred vision following treatment with dabrafenib and trametinib [time to reactions onsets not stated]. The woman, who was diagnosed with an anaplastic ganglioglioma (WHO grade III), underwent surgery and began adjuvant radiotherapy. However, 8 days following surgery, a repeat MRI study of her brain and spine revealed tumour progression with extensive leptomeningeal disease. Later, she was considered for combination therapy of radiation with BRAF and MEK inhibitors, dabrafenib and trametinib, respectively. She received eight 30 day cycles of oral dabrafenib 150mg twice daily and oral trametinib 2mg daily. She developed mild side-effects during the treatment. She reported occasional nausea, which was adequately controlled with ondansetron. She also developed peripheral oedema in the arms and legs as well as blurred vision, which improved over the time period. Three months following therapy, MRI demonstrated a marked reduction in the tumour burden, which was stable at 6 months. Also, she showed significant improvement in her functional status. Author comment: "The therapy was overall well-tolerated, with mild and expected side effects. She complained of occasional nausea, which was adequately http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Dabrafenib/trametinib

Reactions Weekly , Volume 1704 (1) – Jun 2, 2018

Dabrafenib/trametinib

Abstract

Reactions 1704, p130 - 2 Jun 2018 Blurred vision, nausea and peripheral oedema: case report A 51-year-old woman developed occasional nausea, peripheral oedema and blurred vision following treatment with dabrafenib and trametinib [time to reactions onsets not stated]. The woman, who was diagnosed with an anaplastic ganglioglioma (WHO grade III), underwent surgery and began adjuvant radiotherapy. However, 8 days following surgery, a repeat MRI study of her brain and spine revealed tumour...
Loading next page...
 
/lp/springer-journals/dabrafenib-trametinib-F3C2LYBFs9
Publisher
Springer Journals
Copyright
Copyright © 2018 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-9954
eISSN
1179-2051
DOI
10.1007/s40278-018-46773-3
Publisher site
See Article on Publisher Site

Abstract

Reactions 1704, p130 - 2 Jun 2018 Blurred vision, nausea and peripheral oedema: case report A 51-year-old woman developed occasional nausea, peripheral oedema and blurred vision following treatment with dabrafenib and trametinib [time to reactions onsets not stated]. The woman, who was diagnosed with an anaplastic ganglioglioma (WHO grade III), underwent surgery and began adjuvant radiotherapy. However, 8 days following surgery, a repeat MRI study of her brain and spine revealed tumour progression with extensive leptomeningeal disease. Later, she was considered for combination therapy of radiation with BRAF and MEK inhibitors, dabrafenib and trametinib, respectively. She received eight 30 day cycles of oral dabrafenib 150mg twice daily and oral trametinib 2mg daily. She developed mild side-effects during the treatment. She reported occasional nausea, which was adequately controlled with ondansetron. She also developed peripheral oedema in the arms and legs as well as blurred vision, which improved over the time period. Three months following therapy, MRI demonstrated a marked reduction in the tumour burden, which was stable at 6 months. Also, she showed significant improvement in her functional status. Author comment: "The therapy was overall well-tolerated, with mild and expected side effects. She complained of occasional nausea, which was adequately

Journal

Reactions WeeklySpringer Journals

Published: Jun 2, 2018

References